atenolol has been researched along with Disease Exacerbation in 19 studies
Atenolol: A cardioselective beta-1 adrenergic blocker possessing properties and potency similar to PROPRANOLOL, but without a negative inotropic effect.
atenolol : An ethanolamine compound having a (4-carbamoylmethylphenoxy)methyl group at the 1-position and an N-isopropyl substituent.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The European Lacidipine Study on Atherosclerosis (ELSA) was a randomized, double-blind, multicenter trial comparing the effects of a 4-year treatment with either lacidipine or atenolol on progression of carotid atherosclerosis in patients with moderate hypertension." | 9.30 | Serum uric acid and resistance to antihypertensive treatment: data from the European Lacidipine Study on Atherosclerosis. ( Bombelli, M; Cuspidi, C; Facchetti, R; Grassi, G; Macchiarulo, M; Maggiolini, D; Mancia, G; Parati, G, 2019) |
| "Long-term outcome of Marfan syndrome patients randomly assigned to losartan or atenolol showed no differences in aortic dilation rate or presence of clinical events between treatment groups." | 9.27 | Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome. ( Evangelista, A; Forteza, A; García-Dorado, D; González Mirelis, J; Gutiérrez, L; Ibáñez, B; Rodríguez-Palomares, J; Sánchez, V; Teixido-Tura, G, 2018) |
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 9.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| "One hundred and nineteen patients with class II or III heart failure, left ventricular ejection fraction < or = 25% and treatment with 40 mg enalapril daily were given an initial challenge dose of atenolol 12." | 9.09 | Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril. ( Berger, R; Frey, B; Pacher, R; Stanek, B; Strametz-Juranek, J; Sturm, B, 2000) |
| "The European Lacidipine Study on Atherosclerosis (ELSA) was a randomized, double-blind, multicenter trial comparing the effects of a 4-year treatment with either lacidipine or atenolol on progression of carotid atherosclerosis in patients with moderate hypertension." | 5.30 | Serum uric acid and resistance to antihypertensive treatment: data from the European Lacidipine Study on Atherosclerosis. ( Bombelli, M; Cuspidi, C; Facchetti, R; Grassi, G; Macchiarulo, M; Maggiolini, D; Mancia, G; Parati, G, 2019) |
| "Long-term outcome of Marfan syndrome patients randomly assigned to losartan or atenolol showed no differences in aortic dilation rate or presence of clinical events between treatment groups." | 5.27 | Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome. ( Evangelista, A; Forteza, A; García-Dorado, D; González Mirelis, J; Gutiérrez, L; Ibáñez, B; Rodríguez-Palomares, J; Sánchez, V; Teixido-Tura, G, 2018) |
| "In the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study, there was a 25% risk reduction for stroke with angiotensin receptor blocker-based therapy (losartan) as compared with beta-blocker-based therapy (atenolol) despite comparable blood pressure reductions." | 5.12 | Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy. ( Fossum, E; Høieggen, A; Ibsen, H; Julius, S; Kjeldsen, SE; Olsen, MH; Reims, HM; Wachtell, K; Wan, Y, 2006) |
| "The European Lacidipine Study on Atherosclerosis (ELSA) was a randomized, double-blind trial in 2334 patients with hypertension that compared the effects of a 4-year treatment based on either lacidipine or atenolol on an index of carotid atherosclerosis, the mean of the maximum intima-media thicknesses (IMT) in far walls of common carotids and bifurcations (CBM(max))." | 5.10 | Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial. ( Bond, MG; Dal Palù, C; Eckes, L; Hansson, L; Hennig, M; Magnani, B; Mancia, G; Neiss, A; Rahn, KH; Reid, JL; Rizzini, P; Rodicio, J; Safar, M; Zanchetti, A, 2002) |
| "One hundred and nineteen patients with class II or III heart failure, left ventricular ejection fraction < or = 25% and treatment with 40 mg enalapril daily were given an initial challenge dose of atenolol 12." | 5.09 | Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril. ( Berger, R; Frey, B; Pacher, R; Stanek, B; Strametz-Juranek, J; Sturm, B, 2000) |
| "This study, ancillary to the International Nifedipine GITS Study: Intervention as a Goal in Hypertension Treatment (INSIGHT), involved nifedipine 30 mg or co-amilozide (hydrochlorothiazide 25 mg and amiloride 2." | 5.09 | Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes. ( Gariépy, J; Levenson, J; Moyse, D; Simon, A, 2001) |
| "Propranolol users were significantly less likely to present with a T4 (odds ratio [OR], 0." | 1.37 | Beta blockers and breast cancer mortality: a population- based study. ( Barron, TI; Bennett, K; Connolly, RM; Sharp, L; Visvanathan, K, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (5.26) | 18.2507 |
| 2000's | 13 (68.42) | 29.6817 |
| 2010's | 4 (21.05) | 24.3611 |
| 2020's | 1 (5.26) | 2.80 |
| Authors | Studies |
|---|---|
| Huang, KY | 1 |
| Tseng, PT | 1 |
| Wu, YC | 1 |
| Tu, YK | 1 |
| Stubbs, B | 1 |
| Su, KP | 1 |
| Matsuoka, YJ | 1 |
| Hsu, CW | 1 |
| Lin, CH | 1 |
| Chen, YW | 1 |
| Lin, PY | 1 |
| Teixido-Tura, G | 1 |
| Forteza, A | 1 |
| Rodríguez-Palomares, J | 1 |
| González Mirelis, J | 1 |
| Gutiérrez, L | 1 |
| Sánchez, V | 1 |
| Ibáñez, B | 1 |
| García-Dorado, D | 1 |
| Evangelista, A | 1 |
| Bombelli, M | 1 |
| Macchiarulo, M | 1 |
| Facchetti, R | 1 |
| Maggiolini, D | 1 |
| Cuspidi, C | 1 |
| Parati, G | 1 |
| Mancia, G | 3 |
| Grassi, G | 1 |
| Barron, TI | 1 |
| Connolly, RM | 1 |
| Sharp, L | 1 |
| Bennett, K | 1 |
| Visvanathan, K | 1 |
| Gugssa, SA | 1 |
| Johnston, JC | 1 |
| Zanchetti, A | 2 |
| Bond, MG | 2 |
| Hennig, M | 2 |
| Neiss, A | 1 |
| Dal Palù, C | 1 |
| Hansson, L | 1 |
| Magnani, B | 1 |
| Rahn, KH | 1 |
| Reid, JL | 1 |
| Rodicio, J | 1 |
| Safar, M | 1 |
| Eckes, L | 2 |
| Rizzini, P | 1 |
| Tang, R | 1 |
| Hollweck, R | 1 |
| Micheli, D | 1 |
| Matthews, DR | 1 |
| Stratton, IM | 1 |
| Aldington, SJ | 1 |
| Holman, RR | 1 |
| Kohner, EM | 1 |
| Yokoyama, H | 1 |
| Averill, DB | 1 |
| Brosnihan, KB | 1 |
| Smith, RD | 1 |
| Schiffrin, EL | 1 |
| Ferrario, CM | 1 |
| Shangina, OA | 1 |
| Kostin, VI | 1 |
| Koturga, LI | 1 |
| Fossum, E | 1 |
| Olsen, MH | 1 |
| Høieggen, A | 1 |
| Wachtell, K | 1 |
| Reims, HM | 1 |
| Kjeldsen, SE | 1 |
| Ibsen, H | 1 |
| Wan, Y | 1 |
| Julius, S | 1 |
| Kamgar, M | 1 |
| Nobakhthaghighi, N | 1 |
| Shamshirsaz, AA | 1 |
| Estacio, RO | 1 |
| McFann, KK | 1 |
| Schrier, RW | 1 |
| Selamet Tierney, ES | 1 |
| Feingold, B | 1 |
| Printz, BF | 1 |
| Park, SC | 1 |
| Graham, D | 1 |
| Kleinman, CS | 1 |
| Mahnke, CB | 1 |
| Timchak, DM | 1 |
| Neches, WH | 1 |
| Gersony, WM | 1 |
| Lely, AT | 1 |
| van der Kleij, FG | 1 |
| Kistemaker, TJ | 1 |
| Apperloo, AJ | 2 |
| de Jong, PE | 2 |
| de Zeeuw, D | 2 |
| Navis, G | 1 |
| Nussberger, J | 1 |
| Aubert, JF | 1 |
| Bouzourene, K | 1 |
| Pellegrin, M | 1 |
| Hayoz, D | 1 |
| Mazzolai, L | 1 |
| van Essen, GG | 1 |
| Rensma, PL | 1 |
| Stegeman, CA | 1 |
| Sluiter, WJ | 1 |
| Sturm, B | 1 |
| Pacher, R | 1 |
| Strametz-Juranek, J | 1 |
| Berger, R | 1 |
| Frey, B | 1 |
| Stanek, B | 1 |
| Simon, A | 1 |
| Gariépy, J | 1 |
| Moyse, D | 1 |
| Levenson, J | 1 |
| Einecke, D | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Melablock: A Multicentre Randomized, Double---blinded and Placebo---controlled Clinical Trial on the Efficacy and Safety of Once Daily Propranolol 80 mg Retard for the Prevention of Cutaneous Malignant Melanoma Recurrence[NCT02962947] | Phase 2/Phase 3 | 546 participants (Anticipated) | Interventional | 2017-06-30 | Not yet recruiting | ||
| The Effect of Reducing the Intraocular Pressure by Using Alphagan Drops and Macular Edema in Patients With Diabetic Macular Edema[NCT02718547] | 25 participants (Anticipated) | Interventional | 2017-03-26 | Recruiting | |||
| A Triple-Blind, Parallel Study to Investigate the Effect of Losartan Versus Atenolol on the Reduction of Morbidity and Mortality in Hypertensive Patients With Left Ventricular Hypertrophy[NCT00338260] | Phase 3 | 496 participants (Actual) | Interventional | 1995-06-30 | Completed | ||
| Effects of Losartan vs. Nebivolol vs. the Association of Both on the Progression of Aortic Root Dilation in Marfan Syndrome (MFS) With FBN1 Gene Mutations.[NCT00683124] | Phase 3 | 291 participants (Anticipated) | Interventional | 2008-07-31 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
2 reviews available for atenolol and Disease Exacerbation
| Article | Year |
|---|---|
Do beta-adrenergic blocking agents increase asthma exacerbation? A network meta-analysis of randomized controlled trials.
Topics: Administration, Oral; Adrenergic beta-Antagonists; Atenolol; Bisoprolol; Cardiovascular Diseases; Ce | 2021 |
Syphilitic aortic aneurysm with spastic paraparesis: a novel presentation and review of the literature.
Topics: Aorta, Thoracic; Aortic Aneurysm, Thoracic; Atenolol; Disease Outbreaks; Disease Progression; Drug T | 2012 |
10 trials available for atenolol and Disease Exacerbation
| Article | Year |
|---|---|
Losartan Versus Atenolol for Prevention of Aortic Dilation in Patients With Marfan Syndrome.
Topics: Adrenergic beta-1 Receptor Antagonists; Adult; Angiotensin II Type 1 Receptor Blockers; Aorta; Aorti | 2018 |
Serum uric acid and resistance to antihypertensive treatment: data from the European Lacidipine Study on Atherosclerosis.
Topics: Antihypertensive Agents; Atenolol; Atherosclerosis; Blood Pressure; Carotid Artery Diseases; Dihydro | 2019 |
Calcium antagonist lacidipine slows down progression of asymptomatic carotid atherosclerosis: principal results of the European Lacidipine Study on Atherosclerosis (ELSA), a randomized, double-blind, long-term trial.
Topics: Aged; Aged, 80 and over; Antihypertensive Agents; Atenolol; Blood Pressure; Calcium Channel Blockers | 2002 |
Absolute and relative changes in carotid intima-media thickness and atherosclerotic plaques during long-term antihypertensive treatment: further results of the European Lacidipine Study on Atherosclerosis (ELSA).
Topics: Aged; Antihypertensive Agents; Atenolol; Carotid Artery Diseases; Carotid Artery, Common; Carotid Ar | 2004 |
Risks of progression of retinopathy and vision loss related to tight blood pressure control in type 2 diabetes mellitus: UKPDS 69.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Blood Glucose; Bloo | 2004 |
Long-term effects of a losartan- compared with an atenolol-based treatment regimen on carotid artery plaque development in hypertensive patients with left ventricular hypertrophy: ICARUS, a LIFE substudy.
Topics: Adrenergic beta-Antagonists; Aged; Angiotensin II Type 1 Receptor Blockers; Arteriosclerosis; Atenol | 2006 |
Impact of the preintervention rate of renal function decline on outcome of renoprotective intervention.
Topics: Adult; Antihypertensive Agents; Atenolol; Blood Pressure; Creatinine; Disease Progression; Enalapril | 2008 |
Are angiotensin converting enzyme inhibitors superior to beta blockers in retarding progressive renal function decline?
Topics: Adolescent; Adrenergic beta-Antagonists; Adult; Aged; Angiotensin-Converting Enzyme Inhibitors; Aten | 1997 |
Effect of beta 1 blockade with atenolol on progression of heart failure in patients pretreated with high-dose enalapril.
Topics: Adrenergic beta-Antagonists; Angiotensin-Converting Enzyme Inhibitors; Atenolol; Disease Progression | 2000 |
Differential effects of nifedipine and co-amilozide on the progression of early carotid wall changes.
Topics: Aged; Aged, 80 and over; Amiloride; Antihypertensive Agents; Atenolol; Blood Pressure; Carotid Arter | 2001 |
7 other studies available for atenolol and Disease Exacerbation
| Article | Year |
|---|---|
Beta blockers and breast cancer mortality: a population- based study.
Topics: Adrenergic beta-Antagonists; Aged; Atenolol; Breast Neoplasms; Disease Progression; Female; Humans; | 2011 |
Role of blood pressure reduction in prevention of cardiac and vascular hypertrophy.
Topics: Adrenergic beta-Antagonists; Angiotensin I; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; | 2005 |
[Effects of therapy with various groups of antianginal agents on life quality of the elderly with coronary heart disease and comorbid depression].
Topics: Adrenergic beta-Antagonists; Age Factors; Aged; Atenolol; Calcium Channel Blockers; Depression; Dise | 2005 |
Impaired fibrinolytic activity in type II diabetes: correlation with urinary albumin excretion and progression of renal disease.
Topics: Aged; Albuminuria; Antihypertensive Agents; Atenolol; Cardiovascular Diseases; Cohort Studies; Creat | 2006 |
Beta-blocker therapy does not alter the rate of aortic root dilation in pediatric patients with Marfan syndrome.
Topics: Adolescent; Adrenergic beta-Antagonists; Aorta, Thoracic; Atenolol; Child; Dilatation, Pathologic; D | 2007 |
Renin inhibition by aliskiren prevents atherosclerosis progression: comparison with irbesartan, atenolol, and amlodipine.
Topics: Amides; Amlodipine; Animals; Antihypertensive Agents; Apolipoproteins E; Atenolol; Atherosclerosis; | 2008 |
[ELSA Studies studies progression of atherosclerosis. Calcium antagonist arrests the process more than a beta-blocker].
Topics: Adrenergic beta-Antagonists; Arteriosclerosis; Atenolol; Calcium Channel Blockers; Dihydropyridines; | 2001 |